ClinicalTrials.gg
CompletedNCT02443324Updated Jul 31, 2024Results posted

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

A Phase 1 interventional study of Ramucirumab and Pembrolizumab in Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction and Non-small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 22 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-31.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
175
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 9 under way, 2 of them phase 3. Ramucirumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
6th of 24
175 · median 74
Started
2015
with 1 other
Phase 1
4 of 24
none open now
Registered
8th of 24
by date
Lead sponsor
10 of 24
Eli Lilly and Company

Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is one of 2 that started in 2015, is one of 4 in phase 1, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ramucirumab

Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), transitional cell carcinoma of the urothelium, or biliary tract cancer (BTC).

03

Conditions studied

  • Gastric Adenocarcinoma
  • Adenocarcinoma of the Gastroesophageal Junction
  • Non-small Cell Lung Cancer
  • Carcinoma, Transitional Cell
  • Biliary Tract Cancer

Keywords

  • immuno-oncology
  • Vascular Endothelial Growth Factor (VEGF)
  • angiogenesis
  • PD-1
  • carcinoma of the bladder
  • carcinoma of the urethra
  • carcinoma of the ureter
  • carcinoma of the renal pelvis
  • carcinoma of the biliary tract
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • disease or locally advanced, unresectable disease.

    • Has histopathologically confirmed gastric or GEJ adenocarcinoma with documented disease progression after 0-2
    • Has histopathologically confirmed nonsquamous or squamous NSCLC with documented disease progression after 0-3 prior lines of systemic therapy
    • Has histopathologically confirmed transitional cell carcinoma of the urothelium (bladder, urethra, or renal pelvis) with documented disease progression after 1-3 prior lines of systemic therapy
    • Has confirmed biliary tract adenocarcinoma with documented progression after 1-2 prior lines of systemic therapy
  • Availability of tumor tissue for biomarker analysis from a newly obtained core or excisional or willing to undergo a tumor biopsy. For first line NSCLC participants only, expression should be 1% or higher.
  • Have an Performance Status of 0 or 1.
  • Has adequate organ function.
  • Have an anticipated of ≥3 months.

Exclusion criteria

Exclusion Criteria:

  • Have known .
  • Has received ≥3 lines of prior systemic therapy for gastric or GEJ adenocarcinoma and BTC or ≥4 lines for NSCLC or urothelial cancer.
  • Has active disease.
  • Known (HIV) infection.
  • Known active or infection.
  • Has received any previous systemic therapy targeting vascular endothelial growth factor (VEGF) or VEGF receptor, or programmed death (PD) 1 or PD-ligand 1/2 signaling pathways.
  • Have received a within 30 days prior to enrollment. Seasonal flu vaccines that do not contain live virus are permitted.
  • Have had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollment.
  • Have an elective or a planned major surgery during the course of the trial or has undergone major surgery within 28 days prior to enrollment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Cohort A

    Participants with gastroesophageal junction (GEJ) cancer \[Second-Third Line (L)\] received 8 milligrams per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 for every 3 weeks (Q3W) of a 21-day cycle.

    Drug: Ramucirumab · Drug: Pembrolizumab

  • Experimental
    Cohort A1

    Participants with BTC cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.

    Drug: Ramucirumab

  • Experimental
    Cohort A2

    Participants with Gastric-GEJ cancer (First L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.

    Drug: Ramucirumab · Drug: Pembrolizumab

  • Experimental
    Cohort B

    Participants with Gastric-GEJ cancer (Second-Third L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.

    Drug: Ramucirumab · Drug: Pembrolizumab

  • Experimental
    Cohort C

    Participants with NSCLC (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.

    Drug: Ramucirumab · Drug: Pembrolizumab

  • Experimental
    Cohort D

    Participants with Urothelial cancer (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.

    Drug: Ramucirumab · Drug: Pembrolizumab

  • Experimental
    Cohort E

    Participants with NSCLC cancer (First L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.

    Drug: Ramucirumab · Drug: Pembrolizumab

Interventions

  • Administered IV

    Also known as: LY3009806, IMC-1121B, Cyramza

  • Administered IV

    Also known as: MK3475

06

What researchers measure

Primary outcomes

  1. Phase 1a: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)

    DLT is defined as an Adverse Event (AE) that is likely related to study medication or combination,and fulfills any one of following criteria:Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0): Grade (Gr) 3 and 4 nonlaboratory toxicity (tox),Any Gr 3 or 4 laboratory value if medical intervention is required to treat participant (pt) or abnormality persists for \>1 week;Hematologic tox:Gr 4 toxicity lasting ≥ 7 days,or Gr 3 thrombocytopenia if associated with bleeding and requires platelet transfusion,or Febrile neutropenia Gr 3 or Gr 4;GR 5 tox (death);Any toxicity that is possibly related to study treatment that requires withdrawal of pt from study during Cycle 1,A delay of \> 14 days due to persistent Grade ≥ 2 toxicities in initiating Cycle 2,with exception of Grade 2 fatigue;Any infusion or hypersensitivity reactions are NOT a DLT. A summary of other nonserious AEs and all Serious AEs,regardless of causality is located in Reported Adverse Event section.

    Time frame: Cycle 1 (21 Days)

Secondary outcomes

  1. Phase 1a and 1b: Percentage of Participants Who Achieve Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]

    Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Baseline to Measured Progressive Disease (Up to 24 Months)

  2. Phase 1a and 1b: Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]

    Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. Participants who do not have any postbaseline tumor response assessments for any reason were considered.

    Time frame: Baseline to Measured Progressive Disease (Up to 24 Months)

  3. Phase 1a and 1b: Duration of Response (DoR)

    The duration of response is defined only for responders (patients with a confirmed CR or PR). It is measured from the date of first evidence of a confirmed CR or PR to the date of objective progression or the date of death due to any cause, whichever is earlier. If a responder is not known to have died or have objective progression as of the data inclusion cutoff date, DoR will be censored at the date of the last complete objective progression-free disease assessment (CR or PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

    Time frame: Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up to 24 Months)

  4. Phase 1a and 1b: Time to First Response (TTR)

    TTR is defined as the time from the date of first study treatment until the first evidence of a confirmed CR or PR.

    Time frame: Baseline to Date of CR or PR (Up to 24 Months)

  5. Phase 1a and 1b: Progression Free Survival (PFS)

    PFS is defined as the time from the date of first study treatment until the date of the first observed radiographically documented progressive disease (PD) or death due to any cause, whichever is earlier. PD was determined using RECIST criteria. PD is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.

    Time frame: Baseline to PD or Death of Any Cause (Up to 24 Months)

  6. Phase 1a and 1b: Overall Survival (OS)

    The OS time is defined as the time from baseline to the date of death from any cause. If a participant is not known to have died on or before the date of data cut-off, OS data will be censored on the last date (on or before the cut-off date) the participant was known to be alive.

    Time frame: Baseline to Death from Any Cause (Up to 24 Months)

  7. Phase 1a and 1b: Pharmacokinetics (PK): Minimum Trough Concentration (Cmin) of Ramucirumab

    PK: Cmin of Ramucirumab following administration every 3 weeks.

    Time frame: Phase 1a (Gastric-GEJ or BTC participants (pts)): Week (Wk) 1, 3, 6 and 9; Phase 1a (Gastric, NSCLC, or urothelial pts): Wk 3, 6, 9 and 12; Cohort A, A1, A2: Wk 1, 3, 6, 9, 12, 18, 19 and 24; Cohort B,C,D,E: Wk 3, 6, 9, 12, 18, 19 and 24

07

Results

Posted Jul 31, 2024

Participant flow

This study has Phase 1a (dose-limiting toxicity \[DLT\] observation) and expansion Phase 1b (safety and preliminary efficacy) included participants with 2 dosing schedules: Schedule 1: gastroesophageal junction (GEJ) cancer (Cohorts A, A2) and biliary tract cancer (Cohorts A1); Schedule 2: Gastric-GEJ cancer (Cohort B), nonsmall cell lung cancer (NSCLC) (Cohorts C, E), and urothelial cancer (Cohort D).

Participant flow — Overall Study
MilestoneCohort ACohort A1Cohort A2Cohort BCohort CCohort DCohort E
Started24262917282427
Received at least one dose of study drug24262817272426
Phase 1a8000300
Phase 1b16262817242426
Completed0141708
Not completed24252516212419
Withdrew: Death4103132
Withdrew: Lost to follow-up0001010
Withdrew: Physician decision0351102
Withdrew: Progressive disease20201310131710
Withdrew: Withdrawal by subject0031101
Withdrew: Adverse event0130433
Withdrew: Enrolled but never treated0010101

Outcome measures

PrimaryPhase 1a: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)

DLT is defined as an Adverse Event (AE) that is likely related to study medication or combination,and fulfills any one of following criteria:Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0): Grade (Gr) 3 and 4 nonlaboratory toxicity (tox),Any Gr 3 or 4 laboratory value if medical intervention is required to treat participant (pt) or abnormality persists for \>1 week;Hematologic tox:Gr 4 toxicity lasting ≥ 7 days,or Gr 3 thrombocytopenia if associated with bleeding and requires platelet transfusion,or Febrile neutropenia Gr 3 or Gr 4;GR 5 tox (death);Any toxicity that is possibly related to study treatment that requires withdrawal of pt from study during Cycle 1,A delay of \> 14 days due to persistent Grade ≥ 2 toxicities in initiating Cycle 2,with exception of Grade 2 fatigue;Any infusion or hypersensitivity reactions are NOT a DLT. A summary of other nonserious AEs and all Serious AEs,regardless of causality is located in Reported Adverse Event section.

Time frame:
Cycle 1 (21 Days)
Reported as:
Number · participants
Phase 1a: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
participantsCohort ACohort C
Phase 1a: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)10
SecondaryPhase 1a and 1b: Percentage of Participants Who Achieve Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]

Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Baseline to Measured Progressive Disease (Up to 24 Months)
Reported as:
Number · percentage of participants
Phase 1a and 1b: Percentage of Participants Who Achieve Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]
percentage of participantsCohort A and BCohort A1Cohort A2Cohort CCohort DCohort E
Phase 1a and 1b: Percentage of Participants Who Achieve Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]7.3 (1.5 to 19.9)3.8 (0.1 to 19.6)25.0 (10.7 to 44.9)29.6 (13.8 to 50.2)12.5 (2.7 to 32.4)42.3 (23.4 to 63.1)
SecondaryPhase 1a and 1b: Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]

Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. Participants who do not have any postbaseline tumor response assessments for any reason were considered.

Time frame:
Baseline to Measured Progressive Disease (Up to 24 Months)
Reported as:
Number · percentage of participants
Phase 1a and 1b: Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]
percentage of participantsCohort A and BCohort A1Cohort A2Cohort CCohort DCohort E
Phase 1a and 1b: Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]51.2 (35.1 to 67.1)38.5 (20.2 to 59.4)67.9 (47.6 to 84.1)85.2 (66.3 to 95.8)50.0 (29.1 to 70.9)84.6 (65.1 to 95.6)
SecondaryPhase 1a and 1b: Duration of Response (DoR)

The duration of response is defined only for responders (patients with a confirmed CR or PR). It is measured from the date of first evidence of a confirmed CR or PR to the date of objective progression or the date of death due to any cause, whichever is earlier. If a responder is not known to have died or have objective progression as of the data inclusion cutoff date, DoR will be censored at the date of the last complete objective progression-free disease assessment (CR or PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

Time frame:
Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up to 24 Months)
Reported as:
Median · months
Phase 1a and 1b: Duration of Response (DoR)
monthsCohort A and BCohort A1Cohort A2Cohort CCohort DCohort E
Phase 1a and 1b: Duration of Response (DoR)6.7 (4.4 to 17.5)6.0 (NA to NA)NA (9.7 to NA)NA (11.1 to NA)8.3 (4.6 to 16.8)NA (5.2 to NA)
SecondaryPhase 1a and 1b: Time to First Response (TTR)

TTR is defined as the time from the date of first study treatment until the first evidence of a confirmed CR or PR.

Time frame:
Baseline to Date of CR or PR (Up to 24 Months)
Reported as:
Median · months
Phase 1a and 1b: Time to First Response (TTR)
monthsCohort A and BCohort A1Cohort A2Cohort CCohort DCohort E
Phase 1a and 1b: Time to First Response (TTR)1.4 (1.4 to 4.1)2.7 (NA to NA)2.7 (1.3 to 2.8)2.1 (1.3 to 3.0)2.8 (1.3 to 5.5)1.4 (1.2 to 3.0)
SecondaryPhase 1a and 1b: Progression Free Survival (PFS)

PFS is defined as the time from the date of first study treatment until the date of the first observed radiographically documented progressive disease (PD) or death due to any cause, whichever is earlier. PD was determined using RECIST criteria. PD is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.

Time frame:
Baseline to PD or Death of Any Cause (Up to 24 Months)
Reported as:
Median · months
Phase 1a and 1b: Progression Free Survival (PFS)
monthsCohort A and BCohort A1Cohort A2Cohort CCohort DCohort E
Phase 1a and 1b: Progression Free Survival (PFS)2.5 (1.5 to 4.2)1.6 (1.4 to 2.8)5.6 (2.7 to 11.5)9.7 (4.6 to 27.6)1.9 (1.2 to 2.8)9.3 (4.0 to NA)
SecondaryPhase 1a and 1b: Overall Survival (OS)

The OS time is defined as the time from baseline to the date of death from any cause. If a participant is not known to have died on or before the date of data cut-off, OS data will be censored on the last date (on or before the cut-off date) the participant was known to be alive.

Time frame:
Baseline to Death from Any Cause (Up to 24 Months)
Reported as:
Median · months
Phase 1a and 1b: Overall Survival (OS)
monthsCohort A and BCohort A1Cohort A2Cohort CCohort DCohort E
Phase 1a and 1b: Overall Survival (OS)5.9 (4.4 to 10.6)6.4 (4.2 to 13.3)14.6 (5.4 to NA)26.2 (11.8 to NA)6.4 (2.5 to 18.7)NA (13.2 to NA)
SecondaryPhase 1a and 1b: Pharmacokinetics (PK): Minimum Trough Concentration (Cmin) of Ramucirumab

PK: Cmin of Ramucirumab following administration every 3 weeks.

Time frame:
Phase 1a (Gastric-GEJ or BTC participants (pts)): Week (Wk) 1, 3, 6 and 9; Phase 1a (Gastric, NSCLC, or urothelial pts): Wk 3, 6, 9 and 12; Cohort A, A1, A2: Wk 1, 3, 6, 9, 12, 18, 19 and 24; Cohort B,C,D,E: Wk 3, 6, 9, 12, 18, 19 and 24
Reported as:
Geometric mean · micrograms/milliliter (μg/mL)
Phase 1a and 1b: Pharmacokinetics (PK): Minimum Trough Concentration (Cmin) of Ramucirumab
micrograms/milliliter (μg/mL)Phase 1a: Gastric-GEJ or BTCPhase 1 a: Gastric, NSCLC, or Urothelial PatientsCohort ACohort A1Cohort A2Cohort BCohort CCohort DCohort E
Week 150.9 ± 24—44.2 ± 2845.2 ± 4145.9 ± 23————
Week 352 ± 2920.9 ± 3540 ± 4844.1 ± 5745.2 ± 3213.3 ± 9322.5 ± 6220.9 ± 5415.6 ± 70
Week 669 ± 29NA ± NA79.8 ± 3069.1 ± 6861 ± 3825.7 ± 7433.8 ± 6823.3 ± 10219.3 ± 115
Week 9NA ± NA32.7 ± 20.672.8 ± 4694.3 ± 4078.8 ± 3132.7 ± 6040.1 ± 6334.8 ± 7328.6 ± 90
Week 12—NA ± NA89.3 ± 35NA ± NA80.2 ± 3836.8 ± 4847.1 ± 4534.9 ± 14126.3 ± 89
Week 18——92.4 ± 71NA ± NA87.6 ± 4852.7 ± 4544.4 ± 3152.6 ± 3637.1 ± 66
Week 19——149 ± 69NA ± NA120 ± 34————
Week 24——116 ± 83NA ± NA95.7 ± 2743.6 ± 4045 ± 29NA ± NA42.1 ± 87

Adverse events

Collected over Baseline Up to 5.9 Years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A21/24 (87.5%)10/24 (41.7%)23/24 (95.8%)
Cohort A119/26 (73.1%)15/26 (57.7%)26/26 (100%)
Cohort A217/28 (60.7%)16/28 (57.1%)28/28 (100%)
Cohort B13/17 (76.5%)10/17 (58.8%)16/17 (94.1%)
Cohort C16/27 (59.3%)15/27 (55.6%)27/27 (100%)
Cohort D18/24 (75%)16/24 (66.7%)24/24 (100%)
Cohort E9/26 (34.6%)14/26 (53.8%)26/26 (100%)
Most frequent serious events
Showing 10 of 117
Most frequent serious events
EventCohort ACohort A1Cohort A2Cohort BCohort CCohort DCohort E
Abdominal painGastrointestinal disorders3/242/261/282/170/271/241/26
ColitisGastrointestinal disorders0/241/262/282/170/272/240/26
DysphagiaGastrointestinal disorders1/240/261/282/170/270/240/26
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/240/260/282/170/271/240/26
Urinary tract infectionInfections and infestations0/240/263/281/170/270/240/26
Gastrointestinal haemorrhageGastrointestinal disorders2/240/262/281/170/270/240/26
UrosepsisInfections and infestations0/240/261/280/170/272/240/26
Pleural effusionRespiratory, thoracic and mediastinal disorders2/241/261/280/171/270/241/26
Acute myocardial infarctionCardiac disorders0/240/261/280/170/270/242/26
Pericardial effusionCardiac disorders0/240/260/280/170/270/242/26
Most frequent other events
Showing 10 of 166
Most frequent other events
EventCohort ACohort A1Cohort A2Cohort BCohort CCohort DCohort E
FatigueGeneral disorders14/249/2619/289/1710/2711/249/26
NauseaGastrointestinal disorders6/2411/2612/282/175/275/248/26
CoughRespiratory, thoracic and mediastinal disorders5/247/264/283/1711/272/246/26
DiarrhoeaGastrointestinal disorders4/249/2611/286/178/277/248/26
Decreased appetiteMetabolism and nutrition disorders8/247/269/284/1710/278/244/26
HypertensionVascular disorders4/249/2610/284/179/277/246/26
Abdominal painGastrointestinal disorders4/249/265/284/173/274/242/26
ArthralgiaMusculoskeletal and connective tissue disorders4/244/263/280/179/272/243/26
Intermenstrual bleedingReproductive system and breast disorders0/71/180/71/30/60/100/14
HypothyroidismEndocrine disorders3/244/261/282/178/272/242/26

Baseline characteristics

All enrolled participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort ACohort A1Cohort A2Cohort BCohort CCohort DCohort ETotal
Mean56.0 (24.0 to 78.0)62.5 (36.0 to 78.0)63.0 (31.0 to 83.0)61.0 (28.0 to 73.0)65.0 (34.0 to 82.0)63.0 (45.0 to 87.0)63.0 (42.0 to 85.0)61.28 (24.0 to 87.0)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort ACohort A1Cohort A2Cohort BCohort CCohort DCohort ETotal
Female718736101465
Male1782114211412107
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort ACohort A1Cohort A2Cohort BCohort CCohort DCohort ETotal
Hispanic or Latino263234020
Not Hispanic or Latino20191612211025123
Unknown or Not Reported2193310129
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort ACohort A1Cohort A2Cohort BCohort CCohort DCohort ETotal
American Indian or Alaska Native01000001
Asian30010004
Native Hawaiian or Other Pacific Islander00000000
Black or African American10101014
White19231716262222145
More than one race00000000
Unknown or Not Reported1210002318
Region of Enrollment
Region of Enrollment(Participants)Cohort ACohort A1Cohort A2Cohort BCohort CCohort DCohort ETotal
United States32118481147
United Kingdom15117525651
France237182225
Germany01100158
Spain4923138241
08

Study locations

22 sites
  • Yale University School of Medicine
    New Haven, Connecticut 06520-8020, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33916, United States
  • Florida Cancer Specialists and Research Institute
    Saint Petersburg, Florida 33705, United States
  • Tennessee Oncology PLLC
    Chattanooga, Tennessee 37404, United States
  • Sarah Cannon Research Institute SCRI
    Nashville, Tennessee 37203, United States
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37203, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dijon Cedex, 21034, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lille Cedex, 59020, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lyon Cedex 08, 69373, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris CEDEX 05, 75248, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dresden, 01307, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Heidelberg, 69126, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tübingen, 72076, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kochi-Shi, 780-0051, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yamanashi, 400-0124, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08035, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28050, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pamplona, 31008, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, W1G 6AD, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manchester, M20 4BX, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Herbst RS, Arkenau HT, Bendell J, Arrowsmith E, Wermke M, Soriano A, Penel N, Santana-Davila R, Bischoff H, Chau I, Mi G, Wang H, Rasmussen E, Ferry D, Chao BH, Paz-Ares L. Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. J Thorac Oncol. 2021 Feb;16(2):289-298. doi: 10.1016/j.jtho.2020.10.004. Epub 2020 Oct 15. PubMed 33068794 ↗
  • Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol. 2019 Aug;20(8):1109-1123. doi: 10.1016/S1470-2045(19)30458-9. Epub 2019 Jul 10. PubMed 31301962 ↗
  • Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, Walgren RA, Widau RC, Mi G, Jin J, Ferry D, Chau I. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). Oncologist. 2018 Dec;23(12):1407-e136. doi: 10.1634/theoncologist.2018-0044. Epub 2018 May 31. PubMed 29853658 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Aug 2018, 37 months.

Results were first posted in Jul 2024, 5 years 11 months after primary completion.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 37 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2015
First posted
May 13, 2015
StartActual
Jul 29, 2015
Primary completionActual
Aug 31, 2018
CompletionActual
Apr 12, 2022
Results first posted
Jul 31, 2024
Last update
Jul 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02443324
Responsible party
Sponsor
First posted
May 13, 2015
Start date
Jul 29, 2015
Primary completion
Aug 31, 2018
Completion
Apr 12, 2022
Results posted
Jul 31, 2024
Last update
Jul 31, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ramucirumab · Pembrolizumab

Start the discussion